Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.010 GeneticVariation group LHGDN We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2, HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value < 0.0001). 17967182 2007
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms
0.010 Biomarker group BEFREE This study demonstrates that OPCML down-regulation occurs in the majority of brain tumours tested, warranting further investigation of OPCML and other IgLONs in the development and progression of brain tumours. 17239010 2007
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.010 AlteredExpression disease BEFREE In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). 17239010 2007
CUI: C0017638
Disease: Glioma
Glioma
0.010 AlteredExpression disease BEFREE In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). 17239010 2007
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder)
0.010 Biomarker disease BEFREE Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%. 17967182 2007
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.010 GeneticVariation disease BEFREE Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%. 17967182 2007
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma
0.010 AlteredExpression disease BEFREE In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). 17239010 2007
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma
0.010 AlteredExpression disease BEFREE In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). 17239010 2007
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme
0.010 AlteredExpression disease BEFREE In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). 17239010 2007
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.010 AlteredExpression group BEFREE In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). 17239010 2007
CUI: C0038356
Disease: Stomach Neoplasms
Stomach Neoplasms
0.010 AlteredExpression group LHGDN Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray. 17109515 2006
Congenital contractural arachnodactyly
0.020 Biomarker disease BEFREE The combined marker between OPCML and HOXD9 showed sensitivity, specificity, PPV, and NPV of 62.50%, 100%, 100%, and 72.72%, respectively, which may be helpful to prevent a misdiagnosis between CCA and other biliary diseases. 30832707 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.020 GeneticVariation phenotype BEFREE We report the generation of a panel of OPCML variants with representative clinical mutations and demonstrate clear phenotypic effects in vitro and in vivo including changes to anchorage-independent growth, interaction with activated cognate receptor tyrosine kinases, cellular migration, invasion in vitro and tumor growth in vivo. 31316070 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.020 AlteredExpression phenotype BEFREE Immunohistochemistry results showed that the expression of OPCML in gastric cancer was 68.6% and the expression of OPCML was negatively correlated with the depth of tumor invasion and tumor differentiation degree (P < 005); OPCML expression, depth of tumor invasion, lymph node metastasis and distant metastasis were important factors affecting the prognosis of the survival of the patients (P <0.05). 27358143 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.020 Biomarker disease BEFREE Our meta-analysis identified the correlations between a number of aberrant methylated genes (p16, RASSF1A, GSTP1, p14, CDH1, APC, RUNX3, SOCS1, p15, MGMT, SFRP1, WIF1, PRDM2, DAPK1, RARβ, hMLH1, p73, DLC1, p53, SPINT2, OPCML and WT1) and HCC. 27835605 2016
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.020 Biomarker group BEFREE The high frequency of OPCML promoter methylation in urothelial carcinomas suggests an important role for this epigenetic alteration in bladder carcinogenesis, highlighting its potential as an epigenetic biomarker for bladder urothelial carcinoma with prognostic significance. 21273058 2011
Congenital contractural arachnodactyly
0.020 PosttranslationalModification disease BEFREE Low-protein expression was found in >70% of CCA with methylation of OPCML or DcR1. 21448164 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.020 Biomarker disease BEFREE The methylation frequencies of the ten genes examined in HCC were 40.0% for p14 ( ARF ), 60.9% for p15 ( INK4b ), 70.4% for p16 ( INK4a ), 34.8% for p73, 70.4% for GSTP1, 64.3% for MGMT, 13.0% for hMLH1, 59.1% for RARbeta, 82.6% for SOCS-1, and 80.9% for OPCML. 20112070 2010
CUI: C0007097
Disease: Carcinoma
Carcinoma
0.020 Biomarker group BEFREE OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. 18714356 2008
CUI: C0677886
Disease: Epithelial ovarian cancer
Epithelial ovarian cancer
0.020 PosttranslationalModification disease BEFREE Opioid binding protein/cell adhesion molecule-like gene (OPCML), a recently identified tumor-suppressor, is frequently inactivated by allele loss and CpG island promoter methylation in epithelial ovarian cancer. 16384911 2006
CUI: C0677886
Disease: Epithelial ovarian cancer
Epithelial ovarian cancer
0.020 Biomarker disease BEFREE OPCML is frequently somatically inactivated in EOC by allele loss and by CpG island methylation. 12819783 2003
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 AlteredExpression group BEFREE Previous studies have reported that the expression of the opioid binding protein/cell adhesion molecule-like (OPCML) gene was frequently downregulated in various of types of cancer. 29805691 2018
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.030 AlteredExpression disease BEFREE Down-regulated OPCML expression might serve as an independent predictor for unfavorable prognosis of patients, and the biological behavior supports its role as a tumor suppressor in gastric cancer. 28407749 2017
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.030 AlteredExpression disease BEFREE Down-regulated OPCML expression might serve as an independent predictor for unfavorable prognosis of patients, and the biological behavior supports its role as a tumor suppressor in gastric cancer. 28407749 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 AlteredExpression group BEFREE OPCML expression was markedly reduced in tumor tissues and cancer cell lines. 28407749 2017